Soleno Therapeutics (SLNO) Income towards Parent Company (2013 - 2026)

Soleno Therapeutics (SLNO) has reported Income towards Parent Company for 13 consecutive years, with $31.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 171.68% year-over-year to $31.4 million; the TTM figure through Mar 2026 stood at -$185.3 million (up 49.26% YoY), while the FY2025 annual figure was -$53.5 million, up 79.34% from the prior year.
• Income towards Parent Company retreated to $31.4 million in Q1 2026 per SLNO's latest filing, from $43.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $43.4 million in Q4 2025 and bottomed at -$173.9 million in Q2 2025.
• Historically, Income towards Parent Company has averaged -$48.2 million across 5 years, with a median of -$43.8 million in 2025.
• Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 1986.87% — and 2025, when it soared 177.79%.
• Soleno Therapeutics' Income towards Parent Company stood at -$62.6 million in 2022, then surged by 81.09% to -$11.8 million in 2023, then plunged by 370.61% to -$55.7 million in 2024, then surged by 177.79% to $43.4 million in 2025, then fell by 27.63% to $31.4 million in 2026.
• Business Quant data shows SLNO's Income towards Parent Company at $31.4 million in Q1 2026, $43.4 million in Q4 2025, and -$86.2 million in Q3 2025.